Skip to main content
Premium Trial:

Request an Annual Quote

Biomonitor Acquires Irish Cell-based Assay Startup

NEW YORK (GenomeWeb News) – Danish firm Biomonitor said this week that it has acquired Irish startup Neutekbio, a cell-based assay and kit developer founded in 2003.
 
Several news agencies reported that the acquisition price was €7 million ($9 million). A Biomonitor spokesperson claimed that the amount is not accurate but declined to furnish additional details.
 
Biomonitor is a theranostics firm that is developing assays to measure biopharmaceutical drug levels and antibodies to these drugs. It said that the acquisition will complement its current offerings to physicians and clinics treating patients with multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.
 
Galway-based Neutekbio sells the assays and kits, which measure the biological activity of cytokines, under the tradename iLite. Biomonitor intends to retain Neutekbio’s R&D and manufacturing operations in Ireland and its ongoing collaboration with France’s Centre National de la Recherche Scientifique in Paris.
 
Biomonitor received financial support from Danish venture capital firm Sunstone Capital to complete the acquisition of Neutekbio.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.